Skip to content
The Policy VaultThe Policy Vault

AustedoHighmark

Tardive Dyskinesia (TD)

Initial criteria

  • age ≥ 18 years
  • diagnosis of tardive dyskinesia (ICD-10: G24.01, G24.02, G24.09)
  • prescriber attests that the member continues to experience symptoms of TD despite dose reduction, tapering, or discontinuation of the offending medication(s) OR dose reduction, tapering, or discontinuation of the offending medication(s) would not be appropriate

Reauthorization criteria

  • prescriber attests that the member has experienced positive clinical response to therapy

Approval duration

12 months